Merlé Y - Search Results

1

Critical influence of resistance to streptogramin B-type antibiotics on activity of RP 59500 (quinupristin-dalfopristin) in experimental endocarditis due to Staphylococcus aureus.

Fantin B, Leclercq R, Merlé Y, Saint-Julien L, Veyrat C, Duval J, Carbon C. Fantin B, et al. Among authors: merle y. Antimicrob Agents Chemother. 1995 Feb;39(2):400-5. doi: 10.1128/AAC.39.2.400. Antimicrob Agents Chemother. 1995. PMID: 7726505 Free PMC article.

2

Nonparametric population pharmacokinetic analysis of amikacin in neonates, infants, and children.

Tréluyer JM, Merlé Y, Tonnelier S, Rey E, Pons G. Tréluyer JM, et al. Among authors: merle y. Antimicrob Agents Chemother. 2002 May;46(5):1381-7. doi: 10.1128/AAC.46.5.1381-1387.2002. Antimicrob Agents Chemother. 2002. PMID: 11959572 Free PMC article.

3

Population pharmacokinetic analysis of netilmicin in neonates and infants with use of a nonparametric method.

Tréluyer JM, Merlé Y, Semlali A, Pons G. Tréluyer JM, et al. Among authors: merle y. Clin Pharmacol Ther. 2000 Jun;67(6):600-9. doi: 10.1067/mcp.2000.106695. Clin Pharmacol Ther. 2000. PMID: 10872642 Clinical Trial.

4

Potential benefit of Bayesian forecasting for therapeutic drug monitoring in neonates.

Pons G, Tréluyer JM, Dimet J, Merlé Y. Pons G, et al. Among authors: merle y. Ther Drug Monit. 2002 Feb;24(1):9-14. doi: 10.1097/00007691-200202000-00002. Ther Drug Monit. 2002. PMID: 11805715 Review.

5

Drug-drug pharmacodynamic interaction detection by a nonparametric population approach. Influence of design and of interindividual variability.

Merlé Y, Mallet A, Schmautz E. Merlé Y, et al. J Pharmacokinet Biopharm. 1999 Oct;27(5):531-54. doi: 10.1023/a:1023290530853. J Pharmacokinet Biopharm. 1999. PMID: 10948697

6

Impact of model misspecification at design (and/or) estimation step in population pharmacokinetic studies.

Merlé Y, Aouimer A, Tod M. Merlé Y, et al. J Biopharm Stat. 2004 Feb;14(1):213-27. doi: 10.1081/BIP-120028516. J Biopharm Stat. 2004. PMID: 15027510

7

Robust optimal design for the estimation of hyperparameters in population pharmacokinetics.

Tod M, Mentré F, Merlé Y, Mallet A. Tod M, et al. Among authors: merle y. J Pharmacokinet Biopharm. 1998 Dec;26(6):689-716. doi: 10.1023/a:1020703007613. J Pharmacokinet Biopharm. 1998. PMID: 10485081

8

Population pharmacokinetics of clozapine evaluated with the nonparametric maximum likelihood method.

Jerling M, Merlé Y, Mentré F, Mallet A. Jerling M, et al. Among authors: merle y. Br J Clin Pharmacol. 1997 Nov;44(5):447-53. doi: 10.1046/j.1365-2125.1997.t01-1-00606.x. Br J Clin Pharmacol. 1997. PMID: 9384461 Free PMC article.

9

Impact of pharmacokinetic-pharmacodynamic model linearization on the accuracy of population information matrix and optimal design.

Merlé Y, Tod M. Merlé Y, et al. J Pharmacokinet Pharmacodyn. 2001 Aug;28(4):363-88. doi: 10.1023/a:1011534830530. J Pharmacokinet Pharmacodyn. 2001. PMID: 11677932

10

Optimal sampling times for Bayesian estimation of the pharmacokinetic parameters of nortriptyline during therapeutic drug monitoring.

Merlé Y, Mentré F. Merlé Y, et al. J Pharmacokinet Biopharm. 1999 Feb;27(1):85-101. doi: 10.1023/a:1020634813296. J Pharmacokinet Biopharm. 1999. PMID: 10533699

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

18 results

Search Page

Filters